Oregon Measure 109 — Psilocybin therapy is legal and regulated in Oregon. Find a licensed facilitator →
An independent editorial platform built on one premise: the people who need this information most deserve to receive it from the most credible source possible.
"Write like a brilliant science journalist who also lost a friend to PTSD and wants the world to understand what this medicine actually is."
Myco Brief covers the science, law, and human experience of psilocybin therapy. We are not a dispensary, a social media account, or an advocacy organization. We are the reference — the source that veterans, clinicians, journalists, and curious people link to when they need something they can trust.
We report what the research shows, in what populations, under what conditions. We do not tell readers what psilocybin will do for them — we tell them what clinical studies found.
Scientific rigour does not require scientific jargon. We translate the literature into plain language that a veteran, a worried family member, or a skeptical primary care physician can use.
We write for the reader who is not yet convinced. We write as if we are earning their belief through evidence — not assuming it, not demanding it.
No exceptions. If we cannot source it to a primary document, we do not publish it.
We cite the original study, not an article about the study. Links go to PubMed, OHA, ORS — not summaries.
Case studies are labeled as individual experience. Aggregate data is labeled as research.
We report what clinical studies found. We do not tell readers psilocybin will treat their depression or PTSD.
One factual CTA per article, placed contextually, never in the first third of any piece.